|Systematic (IUPAC) name|
|(what is this?)|
Cefoxitin acts by interfering with cell wall synthesis. Its activity spectrum includes a broad range of gram-negative and gram-positive bacteria including anaerobes. It is inactive in vitro to most strains of Pseudomonas aeruginosa and many strains of Enterobacter cloacae. Staphylococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin. 
Spectrum of Bacterial Susceptibility
Cefoxitin has a broad spectrum of activity and has been used in the treatment of skin, bone, respiratory and urinary tract infections. Susceptible bacteria include some Staphylococci, Enterococci, Streptococci, and others. The following represents MIC susceptibility data for a few medically significant microorganisms.
- Escherichia coli: 0.2 μg/ml - 64 μg/ml
- Haemophilus influenzae: 0.5 μg/ml - 12.5 μg/ml
- Streptococcus pneumoniae: 0.2 μg/ml - 1 μg/ml
- Mefoxin Official FDA information at Drugs.com
- Phillips I, Shannon K (1993). "Importance of beta-lactamase induction". Eur J Clin Microbiol Infect Dis. 12 Suppl 1: S19–26. PMID 8477758.
|This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.|